Genedata Expressionist with New Transcriptomics Biomarker Capabilities Advances Drug Development for Personalized Medicine

Expressionist Modules Refiner Array and Analyst Deliver Expanded Processing and Reporting Functionalities

Basel, Switzerland and Lexington, MA (USA), September 14, 2009

Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today announced the release of Genedata Expressionist® 5.3 with enhanced capabilities for transcriptomics-based biomarker discovery for applications in drug profiling and patient selection.

“Expressionist can analyze large amounts of data with highly sophisticated statistical features, not only to visualize your data but also to pre-process them, perform classical statistical analysis, and very high-end classification and prediction,” said Dr. Sergio Baranzini, associate professor in the Department of Neurology at the University of California San Francisco. Baranzini’s team is part of an academic research consortium studying the genetics of multiple sclerosis. “We tested the breadth of software possibilities and Genedata Expressionist goes beyond the capabilities of most software I’ve ever worked with,” continued Baranzini. “Expressionist’s intuitive nature eliminates the trial-and-error process that usually can’t be avoided when working with analytical software.”

Expressionist 5.3 expands the process capabilities of its Refiner Array module to support the next generation of microarrays, including Affymetrix Whole-Transcript and Exon arrays. In response to the growing importance of customized arrays, flexibility in pre-processing raw data has been increased by incorporating array type-specific layout information. Furthermore, data quality assessment functionality as well as access to biological information has been significantly enhanced. To support automated workflow-based SOPs for applications in personalized medicine, a completely new reporting engine has been developed. Processing performance has also been optimized to enable efficient analysis of large-scale microarray projects.

“The release of Expressionist 5.3 is another major step in supporting high-performance data processing and accurate data analysis of the large-scale microarray projects that are becoming standard in drug discovery and related life science applications,” noted Dr. Othmar Pfannes, CEO of Genedata.  Recent Expressionist releases have already augmented technology support in transcriptomics, proteomics and metabolomics as well as enabled high-end cross-omics data processing for mass spectrometry and transcriptomics data.

“Genedata is committed to supporting novel technologies and providing innovative solutions to meet the needs of our users and the demands of constantly evolving technologies,” continued Dr. Pfannes. “As an independent company with a proven track record of delivering best-in-class services to customers around the world, we look forward to collaborating with our partners to improve the efficiency of drug discovery and development in the life sciences.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com

 

Contacts
Allison Kurz
Genedata
Marketing & Communications
Phone: +41 61 511 8459
communications@genedata.com

Jackie Thrasivoulos
Genedata
Public Relations
Phone: +1 508 881 3109
jackie.thrasivoulos@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.